BONUSCAP-ZERTIFIKAT - ELI LILLY & CO | Real-time Bid/Ask 08:53:58 2024-05-28 EDT | ||
| 996.29 EUR / 996.51 EUR | -0.06% |
|
| Current month | +18.76% | ||
| 1 month | +20.39% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 24-05-28 | 1,001 | +0.35% |
| 24-05-27 | 997 | +0.52% |
| 24-05-24 | 991.9 | +0.95% |
| 24-05-23 | 982.6 | +0.89% |
| 24-05-22 | 973.9 | -1.65% |
Delayed Quote Börse Stuttgart
Last update May 28, 2024 at 06:53 am
More quotesStatic data
| Product type | Certificats Bonus |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
UniCredit
|
| WKN | HD52AQ |
| ISIN | DE000HD52AQ1 |
| Date issued | 2024-04-26 |
| Strike | 1,350 $ |
| Maturity | 2025-06-20 (388 Days) |
| Parity | 1 : 1 |
| Emission price | 822.9 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 1,001 € |
|---|---|
| Lowest since issue | 816.6 € |
| Spread | 0.22 € |
| Spread % | 0.02% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
807.4
USD
Average target price
850.8
USD
Spread / Average Target
+5.37%
- Stock Market
- Certificates
- Certificat
